Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Early phase 1Taking people
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
Where
Beijing
Age
18 years to 75 years
People
36
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07793500
Phase 1/2Taking people
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Where
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Hefei, Hongcun, Jinan, Jining, Kunming, Lanzhou, Liaocheng, Nanchang, Nanning, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Wuxi, Xiamen, Xi’an, Xuzhou, Yantai, Yulin, Zhengzhou, Zibo
Age
18 years and over
People
796 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05150691
Phase 1Taking people
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Where
Changsha, Chongqing, Guangzhou, Shanghai, Taiyuan, Wuhan
Age
18 years to 75 years
People
570
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05194982
Phase 2Taking people
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Where
Changchun
Age
18 years to 75 years
People
100
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05924841
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Nanjing, Xian
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 3Taking people
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Xuzhou, Yangzhou, Zhengzhou
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Fujian, Fuzhou, Guandong, Hangzhou, Hefei, Jinan, Jingzhou, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Weihui, Xi'an, Xiangyang, Xuzhou, Yichang, Zhengzhou
Age
18 years and over
People
594 worldwide
Run by
BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01
No phaseNot yet taking people in China
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
Where
Shanghai
Age
18 years to 80 years
People
1,200
Run by
Shanghai Chest Hospital
See details and how to joinNCT07698990
Phase 2Taking people
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Where
Beijing
Age
18 years to 80 years
People
420
Run by
TYK Medicines, Inc
See details and how to joinNCT05948813
Phase 2Taking people
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
Where
Guangzhou, Wuhan
Age
18 years and over
People
32
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07412262
Phase 2Not yet taking people in China
The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
34
Run by
Fudan University
See details and how to joinNCT07780578
No phaseTaking people
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
Where
Chongqing
Age
30 years to 80 years
People
10
Run by
958th Army Hospital of the Chinese People's Liberation Army
See details and how to joinNCT07783971
Phase 2Taking people
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
Where
Shanghai
Age
18 years to 75 years
People
40
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT05987826
Phase 3Taking people
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Where
Guangzhou, Shenyang
Age
18 years and over
People
442
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07739758
No phaseTaking people
Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
Where
Shanghai
Age
18 years and over
People
126
Run by
Energenx Medical LTD.
See details and how to joinNCT06739031
Phase 1Taking people
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Where
Jinan
Age
18 years to 75 years
People
299 worldwide
Run by
Huahui Health
See details and how to joinNCT07623369
Phase 2Not yet taking people in China
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
Where
Tianjin
Age
18 years to 75 years
People
50
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07778940
No phaseTaking people
The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
Where
Shenyang
Age
18 years to 75 years
People
1,500
Run by
Shengjing Hospital
See details and how to joinNCT07779005
Phase 2Taking people
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Beijing
Age
18 years to 75 years
People
30
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07329322
Phase 2Not yet taking people in China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
Where
Chengdu
Age
18 years to 75 years
People
43
Run by
Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT07775040
No phaseTaking people
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
Where
Guangzhou, Nanchang, Shenzhen, Wenzhou
Age
18 years and over
People
150
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07775820
Phase 3Taking people
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Where
Shanghai
Age
18 years and over
People
286
Run by
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
See details and how to joinNCT07109531
Phase 2Taking people
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Where
Guangzhou
Age
18 years and over
People
30
Run by
BeBetter Med Inc
See details and how to joinNCT06514027
No phaseTaking people
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Where
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei, Hubei, Jiangsu, Jiangxi, Jinan, Jinzhou, Nanchang, Nanning, Shandong, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Xiamen, Zhejiang, Zhengzhou
Age
18 years and over
People
150
Run by
Daiichi Sankyo
See details and how to joinNCT06809764
Phase 2Not yet taking people in China
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
Where
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
Age
18 years to 75 years
People
30
Run by
First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT07771764